ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Ipsen S.A.
35.11
0.0000
成交量:
15.00
成交額:
536.58
市值:
116.00億
市盈率:
16.08
高:
35.11
開:
35.11
低:
35.11
收:
35.11
52周最高:
38.95
52周最低:
25.11
股本:
3.30億
流通股本:
1.12億
量比:
0.07
換手率:
0.00%
股息:
0.41
股息率:
1.16%
每股收益(TTM):
2.18
每股收益(LYR):
2.15
淨資產收益率:
10.89%
總資產收益率:
9.58%
市淨率:
2.35
市盈率(LYR):
16.31
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
益普生公佈2025年上半年強勁業績並上調全年財務指引
美通社
·
08/05
益普生2025年第一季度實現穩健業績增長並確認全年業績指引
美通社
·
04/18
在所有治療領域強勁業績的推動下,益普生2024年實現穩健業績增長並確認2025年全年指引
美通社
·
02/17
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IPSEY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPSEY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","market":"US","secType":"STK","nameCN":"Ipsen S.A.","latestPrice":35.11,"timestamp":1764961435827,"preClose":35.11,"halted":0,"volume":15,"delay":15,"floatShares":112371575,"shares":330397936,"eps":2.183055,"marketStatus":"休市中","change":0,"latestTime":"12-05 14:03:55 EST 延時","open":35.11,"high":35.11,"low":35.11,"amount":536.5825000000001,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.183055,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"PINK LIMITED","adjPreClose":35.11,"volumeRatio":0.07015904353579128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","floatShares":112371575,"roa":"9.58%","roe":"10.89%","lyrEps":2.152613,"volumeRatio":0.07015904353579128,"shares":330397936,"dividePrice":0.407664,"high":35.11,"amplitude":0,"preClose":35.11,"low":35.11,"week52Low":25.11,"pbRate":"2.35","psRate":"2.65","week52High":38.95,"institutionHeld":0,"latestPrice":35.11,"eps":2.183055,"divideRate":0.011611,"volume":15,"delay":15,"ttmEps":2.183055,"open":35.11,"prevYearClose":28.97,"prevWeekClose":36.72,"prevMonthClose":36.72,"prevQuarterClose":33.2,"fiveDayClose":36.72,"twentyDayClose":35.32,"sixtyDayClose":34.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPSEY\",params:#limit:5,,,undefined,":[{"date":"2025-06-09","symbol":"IPSEY","amount":0.398618,"announcedDate":"2025-05-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-09","defaultRemindTime":1749475800000,"name":"Ipsen S.A.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-09","currency":"USD","dateTimestamp":1749441600000,"payDate":"2025-06-25"},{"date":"2024-07-25","symbol":"IPSEY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-05-31","symbol":"IPSEY","amount":0.235267,"announcedDate":"2024-05-20","type":"dividend","market":"US","newRecordDate":"2024-05-31","defaultRemindTime":1717162200000,"name":"Ipsen S.A.","recordDate":null,"payableDate":"2024-05-31","currency":"USD","dateTimestamp":1717128000000,"payDate":null},{"date":"2023-06-02","symbol":"IPSEY","amount":0.324045,"announcedDate":"2023-05-19","type":"dividend","market":"US","newRecordDate":"2023-06-05","defaultRemindTime":1685712600000,"name":"Ipsen S.A.","recordDate":"2023-06-27","payableDate":"2023-06-05","currency":"USD","dateTimestamp":1685678400000,"payDate":"2023-06-27"},{"market":"US","date":"2022-10-26","symbol":"IPSEY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1666756800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPSEY\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-07-13","value":0.177552,"currency":"USD"},{"executeDate":"2021-05-28","recordDate":"2021-06-01","paymentDate":"2021-06-09","value":0.275217,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-09","value":0.315063,"currency":"USD"},{"executeDate":"2023-06-02","recordDate":"2023-06-05","paymentDate":"2023-06-27","value":0.324045,"currency":"USD"},{"executeDate":"2024-05-31","recordDate":"2024-05-31","paymentDate":null,"value":0.235267,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPSEY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPSEY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557399040","title":"益普生公佈2025年上半年強勁業績並上調全年財務指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2557399040","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557399040?lang=zh_tw&edition=fundamental","pubTime":"2025-08-05 12:32","pubTimestamp":1754368320,"startTime":"0","endTime":"0","summary":"在此基础上,我很高兴,益普生在销售和利润方面的全年指引做了上调。\" 2025年全年指引 基于上半年强劲的业绩表现,益普生上调了2025年全年财务指引: 以固定汇率计算,总销售额增长超过7.0%。2025年7月23日,欧盟委员会批准益普生将Cabometyx用于治疗既往接受治疗的晚期神经内分泌肿瘤患者。上述所有风险因素均可能影响益普生未来达成财务目标的能力,而这些目标是基于当前可获取信息并假设宏观经济环境相对稳定的前提下设定的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4744400_ZH44400_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","IPSEY","IPN"],"gpt_icon":0},{"id":"2528906912","title":"益普生2025年第一季度實現穩健業績增長並確認全年業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2528906912","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528906912?lang=zh_tw&edition=fundamental","pubTime":"2025-04-18 17:35","pubTimestamp":1744968900,"startTime":"0","endTime":"0","summary":"确认2025年全年财务指引。巴黎2025年4月18日 /美通社/ -- 全球特药领域生物制药公司益普生于4月16日公布了2025年第一季度的财务业绩。对益普生而言,2025年将是重要的一年,多个产品即将上市,我们的产品组合有望达成多项里程碑。\" 全年指引 益普生确认了2025年全年财务指引: 以固定汇率计算,总销售额增长超过5.0%。集团再融资 益普生于3月19日宣布成功完成其首次5亿欧元的评级公募债券发行,票面利率为3.875%,于2032年3月到期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4667912_ZH67912_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","IPSEY","IPN"],"gpt_icon":0},{"id":"2512529945","title":"在所有治療領域強勁業績的推動下,益普生2024年實現穩健業績增長並確認2025年全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2512529945","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512529945?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 17:58","pubTimestamp":1739786280,"startTime":"0","endTime":"0","summary":"本年度还与Skyhawk Therapeutics签署了一项合作协议,开发用于治疗罕见神经系统疾病的RNA调节小分子药物。环境、社会和治理 2024年,益普生采取了重要步骤,以实施可持续发展战略的宏伟目标。经过密集转型项目,目前益普生全球99.8%的电力来自可再生能源。2025年财务指引 益普生为2025财年制定了以下财务指引,其中排除了潜在的后期业务开发交易的任何影响: 以固定汇率计算,总销售额增长超过5.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4620551_ZH20551_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","IPSEY","BK4080","BK4139","ALGS","BK4505","BK4007","BK4231","IPN"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IPSEY\",params:#limit:6,delay:false,,,undefined,":[]}}